References
- 1. Yehuda R, Hoge CW, McFarlane AC et al. Post-traumatic stress disorder. Nat Rev Dis Primers, 2015, 1:15057.
- 2. Yehuda R, Lehrner A, Rosenbaum TY. PTSD and Sexual Dysfunction in Men and Women. J Sex Med, 2015, 12(5):1107-19.
- 3. Watson P. PTSD as a Public Mental Health Priority, Curr Psychiatry Rep, 2019, 21(7):61.
- 4. Benjet C, Bromet E, Karam EG, Kessler RC, et al. The epidemiology of traumatic event exposure worldwide: results from the World Mental Health Survey Consortium. Psychol Med. 2016, 46(2):327-43.
- 5. Krystal JH, Neumeister A. Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience. Brain Res, 2009, 1293:13-23.
- 6. Stein DJ, Ipser JC, Seedat S. Pharmacotherapy for post traumatic stress disorder (PTSD). Cochrane Database Syst Rev, 2006, 2006(1):CD002795.
- 7. Davidson JR. Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale. Int Clin Psychopharmacol, 2004, 19(2):85-7.
- 8. Dieperink M, Erbes C, Leskela J et al. Comparison of treatment for post-traumatic stress disorder among three Department of Veterans Affairs medical centers, Mil Med, 2005, 170(4):305-8.
- 9. Bernardy NC, Hoge CW, & Friedman MJ. VA/DoD Clinical Practice Guideline for the management of posttraumatic stress disorder and acute stress disorder. Washington, DC: United States Departments of Veterans Affairs and Defense, 2017, available at VA/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder, accessed on 9th of June, 2021.
- 10. American Psychological Association. (2017), Clinical practice guideline for the treatment of posttraumatic stress dis order (PTSD) in adults. American Psychological Association Guideline Development Panel for the Treatment of PTSD in Adults, available at: https://www.apa.org/ptsd-guideline/ptsd.pdf, accessed on 9th of June 2021.
- 11. Rauch SL, Shin LM, Phelps EA. Neurocircuitry models of posttraumatic stress disorder and extinction: human neuroimaging research-past, present, and future. Biol Psychiatry, 2006, 60(4):376-82.
- 12. Rauch SL, Shin LM, Whalen PJ, Pitman RK. Neuroimaging and the neuroanatomy of PTSD. CNS Spectr, 1998, 3(suppl 2):30 – 41.
- 13. Horn SR, Charney DS, Feder A. Understanding resilience: New approaches for preventing and treating PTSD. Exp Neurol, 2016, 284(Pt B):119-132.
- 14. Abdallah CG, Averill LA, Akiki TJ et al. The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder. Ann Rev Pharmacol Toxicol, 2019, 59:171-189.
- 15. Rasmusson AM, Pineles SL. Neurotransmitter, Peptide, and Steroid Hormone Abnormalities in PTSD: Biological Endophenotypes Relevant to Treatment. Curr Psychiatry Rep, 2018, 20(7):52.
- 16. Arnsten AF. Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci, 2009, 10(6):410-22.
- 17. Birnbaum S, Gobeske KT, Auerbach J, Taylor JR, Arnsten AF. A role for norepinephrine in stress-induced cognitive deficits: alpha-1-adrenoceptor mediation in the prefrontal cortex. Biol Psychiatry, 1999, 46(9):1266-74.
- 18. Fitzgerald JM, DiGangi JA, Phan KL. Functional Neuroanatomy of Emotion and Its Regulation in PTSD. Harv Rev Psychiatry, 2018, 26(3):116-128.
- 19. Quinones MM, Gallegos AM, Lin FV, Heffner K. Dysregulation of inflammation, neurobiology, and cognitive function in PTSD: an integrative review. Cogn Affect Behav Neurosci, 2020, 20(3):455-480.
- 20. Pan X, Wang Z, Wu X, Wen SW, Liu A. Salivary cortisol in post-traumatic stress disorder: a systematic review and meta-analysis. BMC Psychiatry, 2018, 18(1):324. doi: 10.1186/s12888-018-1910-9.
- 21. Speer KE, Semple S, Naumovski N, D’Cunha NM, McKune AJ. HPA axis function and diurnal cortisol in post-traumatic stress disorder: A systematic review. Neurobiol Stress, 2019, 11:100180.
- 22. Yehuda R, Flory JD, Bierer LM et al. Lower methylation of glucocorticoid receptor gene promoter 1F in peripheral blood of veterans with posttraumatic stress disorder. Biol Psychiatry, 2015, 77(4):356-64.
- 23. Bandelow B, Baldwin D, Abelli M et al. Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World J Biol Psychiatry. 2017 Apr;18(3):162-214.
- 24. Zohar J, Yahalom H, Kozlovsky N et al. High dose hydrocortisone immediately after trauma may alter the trajectory of PTSD: interplay between clinical and animal studies, Eur Neuropsychopharmacol, 2011, (11):796-809.
- 25. Southwick SM, Krystal JH, Bremner JD et al. Noradrenergic and serotonergic function in posttraumatic stress disorder. Arch Gen Psychiatry, 1997, 54(8):749-58.
- 26. Kelmendi B, Adams TG, Yarnell S, Southwick S, Abdallah CG, Krystal JH. PTSD: from neurobiology to pharmacological treatments. Eur J Psychotraumatol, 2016, 7:31858.
- 27. Ramboz S, Oosting R, Amara DA et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci U S A, 1998, 95(24):14476-81.
- 28. Murrough JW, Czermak C, Henry S et al. The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. Arch Gen Psychiatry, 2011, 68(9):892-900.
- 29. Zohar J, Fostick L, Juven-Wetzler A et al. Secondary prevention of chronic PTSD by early and short-term administration of escitalopram: a prospective random ized, placebo-controlled, double-blind trial. The Journal of clinical psychiatry, 2018, 79(2):16m10730. doi: 10.4088/JCP.16m10730.
- 30. Miner LH, Jedema HP, Moore FW, Blakely RD, Grace AA, Sesack SR. Chronic stress increases the plasmalemmal distribution of the norepinephrine transporter and the coexpression of tyrosine hydroxylase in norepinephrine axons in the prefrontal cortex. J Neurosci, 2006, 26(5):1571-8.
- 31. Krystal JH, Webb E, Cooney NL et al. Serotonergic and noradrenergic dysregulation in alcoholism: m-chlorophenylpiperazine and yohimbine effects in recently detoxified alcoholics and healthy comparison subjects. Am J Psychiatry, 1996, 153(1):83-92.
- 32. Southwick SM, Krystal JH, Morgan CA et al. Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry, 1993, 50(4):266-74.
- 33. Raskind MA, Peskind ER, Chow Bet al. Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans. N Engl J Med, 2018, 378(6):507-517.
- 34. Germain A, Richardson R, Moul DE et al. Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US Military Veterans. J Psychosom Res, 2012, 72(2):89-96.
- 35. Brunet A, Saumier D, Liu A, Streiner DL, Tremblay J, Pitman RK. Reduction of PTSD Symptoms With Pre-Reactivation Propranolol Therapy: A Randomized Controlled Trial, Am J Psychiatry, 2018, 175(5):427-433.
- 36. van Zuiden M, Frijling JL, Nawijn L et al. Intranasal Oxytocin to Prevent Posttraumatic Stress Disorder Symptoms: A Randomized Controlled Trial in Emergency Department Patients. Biol Psychiatry, 2017,81(12):1030-1040.
- 37. Flanagan JC, Sippel LM, Wahlquist A, Moran-Santa Maria MM, Back SE. Augmenting Prolonged Exposure therapy for PTSD with intranasal oxytocin: A randomized, placebo-controlled pilot trial. J Psychiatr Res, 2018, 98:64-69.
- 38. Sippel LM, Allington CE, Pietrzak RH, Harpaz-Rotem I, Mayes LC, Olff M. Oxytocin and Stress-related Disorders: Neurobiological Mechanisms and Treatment Opportunities, Chronic Stress (Thousand Oaks), 2017, 1:247054701668799.
- 39. Pitman RK, Rasmusson AM, Koenen KC et al. Biological studies of post-traumatic stress disorder, Nat Rev Neurosci, 2012,13(11):769-87.
- 40. Pennington DL, Abé C, Batki SL, Meyerhoff DJ. A preliminary examination of cortical neurotransmitter levels associated with heavy drinking in posttraumatic stress disorder. Psychiatry Res, 2014, 224(3):281-7.
- 41. Hill MN, Campolongo P, Yehuda R, Patel S. Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder. Neuropsychopharmacology, 2018, 43(1):80-102.
- 42. Bitencourt RM, Pamplona FA, Takahashi RN. Facilitation of contextual fear memory extinction and anti-anxiogenic effects of AM404 and cannabidiol in conditioned rats. Eur Neuropsychopharmacol, 2008, 18(12):849-59.
- 43. Assareh N, Gururajan A, Zhou C, Luo JL, Kevin RC, Arnold JC. Cannabidiol disrupts conditioned fear expression and cannabidiolic acid reduces trauma-induced anxiety-related behaviour in mice. Behav Pharmacol, 2020, 31(6):591-596.
- 44. García-Gutiérrez MS, Navarrete F, Gasparyan A, Austrich-Olivares A, Sala F, Manzanares J. Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders. Biomolecules, 2020, 10(11):1575.
- 45. Elms L, Shannon S, Hughes S, Lewis N. Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series. J Altern Complement Med. 2019, 25(4):392-397.
- 46. Berardi A, Schelling G, Campolongo P. The endocannabinoid system and Post Traumatic Stress Disorder (PTSD): From preclinical findings to innovative therapeutic approaches in clinical settings, Pharmacol Res. 2016, 111:668-678.
- 47. Bitencourt RM, Takahashi RN. Cannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder: From Bench Research to Confirmation in Human Trials. Front Neurosci, 2018, 12:502.
- 48. Cannabidiol (CBD) Critical Review Report, World Health Organization, Expert Committee on Drug Dependence, Geneva, available at CANNABIDIOL (CBD) (who.int), accessed on 9th of June, 2021.
- 49. Britch SC, Babalonis S, Walsh SL. Cannabidiol: pharmacology and therapeutic targets. Psychopharmacology (Berl), 2021, 238(1):9-28.
- 50. Sartori SB, Singewald N. Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders. Pharmacol Ther, 2019, 204:107402.
- 51. Cameron C, Watson D, Robinson J. Use of a synthetic cannabinoid in a correctional population for posttraumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. J Clin Psychopharmacol, 2014, 34(5):559-64.
- 52. Spindle TR, Cone EJ, Goffi E et al. Pharmacodynamic effects of vaporized and oral cannabidiol (CBD) and vaporized CBD-dominant cannabis in infrequent cannabis users. Drug Alcohol Depend, 2020, 211:107937.
- 53. Young MB, Norrholm SD, Khoury LM et al. Inhibition of serotonin transporters disrupts the enhancement of fear memory extinction by 3,4-methylenedioxymethamphetamine (MDMA). Psychopharmacology (Berl), 2017, 234(19):2883-2895.
- 54. Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R. Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline. Front Psychiatry. 2019 Sep 12; 10:650.
- 55. Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Doblin R. The safety and efficacy of {+/-}3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol, 2011, 25(4):439-52.
- 56. Mithoefer MC, Wagner MT, Mithoefer AT et al. Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study. J Psychopharmacol, 2013, 27(1):28-39.
- 57. Jerome L, Feduccia AA, Wang JB et al. Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology (Berl), 2020, 237(8):2485-2497.
- 58. Illingworth BJ, Lewis DJ, Lambarth AT et al. A comparison of MDMA-assisted psychotherapy to non-assisted psychotherapy in treatment-resistant PTSD: A systematic review and meta-analysis. J Psychopharmacol, 2021, 35(5):501-511.
- 59. Schenk S, Newcombe D. Methylenedioxymethamphetamine (MDMA) in Psychiatry: Pros, Cons, and Suggestions. J Clin Psychopharmacol, 2018, 38(6):632-638.
- 60. Morgan L. MDMA-assisted psychotherapy for people diagnosed with treatment-resistant PTSD: what it is and what it isn’t. Ann Gen Psychiatry, 2020, 19:33.
- 61. Jîtcă G, Ősz BE, Tero-Vescan A, Vari CE. Psychoactive Drugs-From Chemical Structure to Oxidative Stress Related to Dopaminergic Neurotransmission. A Review, Antioxidants (Basel), 2021,10(3):381.
- 62. de la Torre R, Farré M. Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci, 2004, 25(10):505-8.